

## RESEARCH ARTICLE

# Amyloid $\beta$ 42 peptide is toxic to non-neural cells in *Drosophila* yielding a characteristic metabolite profile and the effect can be suppressed by PI3K

Mercedes Arnés<sup>1,\*</sup>, Sergio Casas-Tintó<sup>1,\*</sup>, Anders Malmendal<sup>2,‡</sup> and Alberto Ferrús<sup>1,‡</sup>

## ABSTRACT

The human A $\beta$ 42 peptide is associated with Alzheimer's disease through its deleterious effects in neurons. Expressing the human peptide in adult *Drosophila* in a tissue- and time-controlled manner, we show that A $\beta$ 42 is also toxic in non-neural cells, neurosecretory and epithelial cell types in particular. This form of toxicity includes the aberrant signaling by Wingless morphogen leading to the eventual activation of Caspase 3. Preventing Caspase 3 activation by means of p53 keeps epithelial cells from elimination but maintains the A $\beta$ 42 toxicity yielding more severe deleterious effects to the organism. Metabolic profiling by nuclear magnetic resonance (NMR) of adult flies at selected ages post A $\beta$ 42 expression onset reveals characteristic changes in metabolites as early markers of the pathological process. All morphological and most metabolic features of A $\beta$ 42 toxicity can be suppressed by the joint overexpression of PI3K.

**KEY WORDS:** Amyloid  $\beta$ , Metabolomics, NMR, PI3K, Epithelial cells, Wingless

## INTRODUCTION

A $\beta$ 42 is a proteolytic peptide from the amyloid precursor protein (APP), a ubiquitous transmembrane protein whose physiological function is still poorly characterized (Ludewig and Korte, 2016). APP proteolysis can produce two different peptides, A $\beta$ 40 and A $\beta$ 42, which accumulate inside and outside the cell where they may form amyloid fibrils (Gerber et al., 2017; Seipold and Saftig, 2016; Bolduc et al., 2016; Andrew et al., 2016). The second, A $\beta$ 42, is more toxic and seems to be the origin of Alzheimer's disease (AD). The toxicity mechanisms are still largely unknown, but current views indicate that A $\beta$  monomers and fibrils are relatively inert. By contrast, smaller oligomeric aggregates, formed on the pathway between monomer and fibril, are the neurotoxic molecule (Walsh et al., 2002; Lei et al., 2016).

Since AD was first described as a neural disease, the vast majority of studies on A $\beta$ 42 have focused on neurons. This is in spite of early evidence reporting the expression of APP in non-neuronal cells and the secretion of its A $\beta$  peptides (Card et al., 1988; Busciglio et al., 1993). AD-hallmark proteins have been reported in patients

diagnosed with other diseases, such as sporadic inclusion body myositis (Askanas and Engel, 1998) or several forms of autism (Westmark et al., 2016). In the absence of effective treatments for fully developed AD, the only option is to explore procedures for an early diagnosis. In this context, metabolic alterations are part of neurodegenerative disorders, including AD, as supported by studies in animal models and clinical samples from AD patients (reviewed in Barba et al., 2008; Trushina et al., 2013). Potential biomarkers of AD include n-acetylaspartate as a neuronal loss marker, and myo-inositol for gliosis and inflammation. Recently, a 12 plasma metabolite profile specific to superior memory performance in older adults was identified which allowed prediction of which patients with mild cognitive impairment will progress to AD (Mapstone et al., 2017).

Metabolic profiling can be performed by nuclear magnetic resonance (NMR) or mass spectrometry (MS). Perturbations often begin with metabolic changes, hence metabolite profiling by NMR is a good starting point for an early diagnosis, perhaps to be followed by recently developed MS procedures to detect A $\beta$ 42 and tau if their discriminatory value for AD versus other diseases is finally demonstrated (Pottiez et al., 2017; Somers et al., 2017). Here, we use *Drosophila* to reproduce A $\beta$ 42 accumulation and to assay toxicity suppression methods. In particular, we focus on PI3K given its neuroprotective effects (Martin-Pena et al., 2006; Sofola et al., 2010; Cuesto et al., 2011, 2015). Our study focuses on the much-neglected non-neuronal cell types as a strategy towards their potential use in early diagnosis of AD.

## RESULTS AND DISCUSSION

We drive the expression of a construct with two copies of the human A $\beta$ 42 peptide encoding gene (Casas-Tintó et al., 2011) using the binary system Gal4/UAS (Brand and Perrimon, 1993) coupled with the temperature-sensitive repressor Gal80<sup>TS</sup> (McGuire et al., 2003). The time onset was routinely established at day 0-3 of adulthood and the effects were monitored 7 and 15 days later (Fig. 1A).

### A $\beta$ 42 accumulation induces toxicity in neurosecretory cells

Driving A $\beta$ 42 to the nervous system (*elav-Gal4*), from adult day 0-3 onwards (see genotypes in the legend of Fig. 1), all flies exhibit inflated abdomen and proboscis, up to 80% of their normal width, by day 7-10 (Fig. 1B-D). Upon puncture, the inflated structures expelled abundant liquid which suggested a problem with diuresis. To explore this suggestion, we repeated the experiment driving the expression of A $\beta$ 42 to the neurosecretory cells that express the peptide Leucokinin (*leuco-Gal4*). This peptide controls food intake and fluid secretion through the Malpighian tubules (Terhzaz et al., 1999; Al-Anzi et al., 2010; López-Arias et al., 2011). The inflated abdomen phenotype was reproduced (Fig. 1E-G). The phenotype was evident also from the first days of adulthood and continued increasing its severity until death. This feature represents A $\beta$ 42 toxicity in cells outside the neuron type.


<sup>1</sup>Dept. of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, Avda. Doctor Arce, 37, 28002 Madrid, Spain. <sup>2</sup>Biochemistry and Structural Biology, Center for Molecular Protein Science, Department of Chemistry, Lund University, P.O. Box 124, SE-22100 Lund, Sweden.

\*These authors contributed equally to this work

‡Authors for correspondence (aferrus@cajal.csic.es; malmendal@gmail.com)

id A.M., 0000-0002-8413-9717; A.F., 0000-0002-0346-0489

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.



**Fig. 1. The inflated abdomen phenotype induced by Aβ42 is prevented by PI3K overexpression.** (A) Diagram of the temperature shift schedule to inactivate the *Gal80<sup>TS</sup>* repressor, thus allowing UAS-constructs expression. System onset was routinely established at day 0-3 after eclosion and the effects were monitored 7 or 15 days later. (B) Representative images of 15-day-old adult flies expressing: *UAS-LacZ* (control), *UAS-Aβ42(2x)*, *UAS-PI3K<sup>CAAX</sup>* and *UAS-PI3K<sup>CAAX</sup>/UAS-Aβ42(2x)* under *elav<sup>C155</sup>-Gal4/Tub-Gal80<sup>TS</sup>* driver. (C) Lateral views of Aβ42 and PI3K/Aβ42 genotypes. (D) Lateral views of head and proboscis of Aβ42 and PI3K/Aβ42. (E) Representative images of 15-day-old adult flies expressing: *UAS-LacZ* (control), *UAS-Aβ42(2x)*, *UAS-PI3K<sup>CAAX</sup>* and *UAS-PI3K<sup>CAAX</sup>/UAS-Aβ42(2x)* under the *Leuco-Gal4* driver. (F, G) Lateral views of whole body (F) or head-proboscis (G) of Aβ42 and PI3K/Aβ42 flies.


In a previous study, we had shown that overexpression of PI3K delays the deleterious features of aged neurons (Martin-Pena et al., 2006). To assay the possible counter-effect of PI3K upon this non-neuronal toxicity, we co-expressed Aβ42 and a constitutive active form of PI3K, PI3K<sup>CAAX</sup>, in the *leuco-Gal4* domain. In 100% of individuals ( $n=46$ ), the inflated abdomen phenotype did not develop at any time of adulthood (Fig. 1B-G). Thus, the toxicity of Aβ42 in this non-neuronal cell type can be suppressed by PI3K. These initial observations prompted the analysis of additional cell types.

#### Epithelial wing cells are also sensitive to Aβ42 toxicity

The widely used drivers *elav-Gal4* and *D42-Gal4* are considered nervous system specific. However, we demonstrated recently that these two drivers, as well as others, exhibit a transient expression in wing imaginal discs during the first 12 h of

development (Casas-Tintó et al., 2017). Taking advantage of this feature (Fig. S2), we searched for deleterious effects of Aβ42 in adult wings to determine if the toxicity in neurosecretory cells is also evident in other cell types early in development. The continuous expression of Aβ42 during development yielded adult wings with severe abnormalities (Fig. 2A). The co-expression of PI3K<sup>CAAX</sup> suppressed the morphological abnormalities of the adult wings (Fig. 2A). Only 5% of Aβ42/PI3K-expressing adults showed some morphological aberration in their wings and, when present, the defect was reduced (see adult wing in the right panel of Fig. 2A). These findings confirmed the toxicity of Aβ42 in non-neuronal cells and its suppression by PI3K.

Since the *D42-Gal4* driver is active in wing discs at early stages of development (Casas-Tintó et al., 2017), we questioned if the Aβ42 toxicity could elicit cell death by apoptosis. To that end, we



**Fig. 2. Wing and apoptotic defects in Aβ42 flies are prevented by PI3K.** (A) Adult wings of genotypes: *UAS-LacZ* (control), *UAS-PI3K<sup>CAAX</sup>*, *UAS-Aβ42(2x)* and *UAS-PI3K<sup>CAAX</sup>/UAS-Aβ42(2x)* under *D42-Gal4* driver. (B-C') Same genotypes viewed as imaginal wing discs with no activation of Caspase-3. (D-E') Same constructs under *engrailed-Gal4/UAS-GFP<sup>nls</sup>* driver (green). Note the active Caspase-3 cells in the driver domain (D' and E'). (F) Quantification of posterior/anterior, P/A, ratio for Caspase-3 intensities. Bars indicate mean and s.d. Student's *t*-test with \*\*\**P*<0.001. Scale bar: 100 μm.

immunostained third instar larval wing discs for activated Caspase-3. No evidence of apoptosis was obtained either in the Aβ42- or in the Aβ42/PI3K-expressing wing discs (Fig. 2B,C). We suspected that the lack of evidences for Caspase-3 activation could be due to the transient expression of *D42-Gal4* in wing discs (first 12 h of development) (Casas-Tintó et al., 2017). Thus, we repeated the experiment using a permanently expressed driver, *engrailed-Gal4* (*en-Gal4*), which is active in the posterior compartment of the wing. In this experiment, the anterior wing disc compartment serves as internal control. Caspase-3 activation was clearly detected in the posterior, by contrast to the anterior, compartment (Fig. 2D). As in previous cases, the co-expression of PI3K significantly reduced the activated Caspase-3 signal (Fig. 2E,F).


#### Aβ42 toxicity in epithelial cells alters Wingless signaling

In vertebrates, several Wnt family components are dysregulated in AD (Inestrosa and Varela-Nallar, 2014). Some components have also been implicated in synaptogenesis consistent with the synapse loss

observed in the disease (Franciscovich et al., 2008). In view of the toxic effects of human Aβ42 in the fly epithelial cells, we investigated if Aβ42, alone or in conjunction with PI3K, would alter Wingless (*wg*) signaling, a homologue of vertebrate Wnt. To that end, we stained third instar larval wing discs with anti-Wingless (Fig. 3).

The data show a distorted pattern of Wingless expression in the Aβ42-expressing domain (posterior wing compartment, *en-Gal4*) by contrast to the control domain (anterior wing compartment) (Fig. 3A). The distorted expression, however, could be an indirect effect of an aberrant cell shape or cell number, among other factors. To validate the abnormal *Wg* pattern, we monitored the expression of its functional target, Armadillo (Riggleman et al., 1990; Noordermeer et al., 1994). Armadillo/β-catenin expression is also distorted in the Aβ42-expressing domain (Fig. 3C). Consistent with the experiments above, PI3K suppressed the *Wg* and *Arm* alterations caused by Aβ42 (Fig. 3B,D).

The disruption of *Wg* and *Arm* expression could be a cause or consequence of the activation of Caspase-3 and cell apoptosis.



**Fig. 3. A $\beta$ 42 alters Wingless and Armadillo expression in epithelial wing cells and PI3K suppresses the effect.** Wingless (A-B), Armadillo (C-D) and DAPI (magenta) immunostainings from third instar larval wing discs expressing *UAS-A $\beta$ 42(2x)* and *UAS-PI3K<sup>CAAX</sup>/A $\beta$ 42(2x)* under *engrailed-Gal4/UAS-GFP<sup>iris</sup>* driver (green). Dotted line separates anterior and posterior wing compartments. Note the loss of Wingless expression (arrowhead in A') which is restored by PI3K (B'). The same effect is observed for Armadillo (C, C', D, D'). Orthogonal views of the same discs are shown in C'', C''', D'' and D'''. The effects persist when the co-expression of p35 prevents Caspase-3 activation and apoptosis (E-E''). Scale bar: 100  $\mu$ m.

To sort out the hierarchical order of events, we prevented apoptosis by the co-expression of the baculovirus protein p35 (Hay et al., 1994; Portela et al., 2010). The data show that A $\beta$ 42-expressing cells rescued from cell death, exhibit the characteristic abnormality of Wg expression (Fig. 3E). Thus, the disruption of morphogens Wg and Arm are among the early events of A $\beta$ 42 toxicity. Interestingly, while the A $\beta$ 42-expressing flies in the *D42-Gal4* or *en-Gal4* domains are still able to reach adulthood and exhibit morphological wing abnormalities (see Fig. 2A), flies co-expressing p35 are lethal. This observation is consistent with the strong effects resulting from preventing apoptosis of unfitted cells for which the term 'undead cells' was coined (Perez-Garijo et al., 2005, 2009). Actually, it is the contrast between the Wg levels of adjacent cells that triggers cell competition and elimination by apoptosis (Vincent et al., 2011).

In summary, A $\beta$ 42 causes toxic effects in non-neuronal cell types, which include early alterations of Wingless and Armadillo signaling, that lead, eventually, to Caspase-3 activation. If the A $\beta$ 42-expressing cells are eliminated by apoptosis and the system is still able to proliferate, the organ integrity may be restored. However, if toxic cells are not eliminated, the deleterious effects for the cell system and the organism are more severe.


#### Metabolic profiling of A $\beta$ 42-expressing flies identifies molecular markers which are suppressed by PI3K

Fly models of AD show changes in the metabolite profile both in nervous and non-nervous tissues (Ott et al., 2016). Thus, we explored the metabolome of adult flies expressing high levels of

A $\beta$ 42, either alone or in combination with PI3K. Expression was triggered at day 0-3 post eclosion in order to avoid potential effects during larval development. The metabolite profile was monitored by NMR 7 and 15 days later (i.e. day 7-10 or 15-18 of adulthood; Fig. 4). In order to focus on non-neuronal tissues, we studied the metabolite response of abdomens. In this body part, the *elav-Gal4* driver shows temporal expression as demonstrated by the GTRACE procedure (Fig. S3).

We used an O2PLS-DA model to visualize the effects of A $\beta$ 42 and PI3K expression (Fig. 4A). The cross-validated scores show a robust separation from the control (green), and those submitted to A $\beta$ 42 (blue) and PI3K expression (red) (Fig. 4A). Metabolite variations along the x-axis include increases in glucose (3.89, 3.47, 3.45, 3.39, 3.23 ppm), histidine (7.78, 7.05, 3.12 ppm), uracil (7.53, 5.79 ppm), phosphocholine (4.15, 3.21 ppm) and lysine (3.01, 1.88, 1.72, 1.44 ppm), and decreases in maltose (5.40, 3.94, 3.90, 3.85, 3.68, 3.61, 3.27 ppm), uridine (7.85, 5.89 ppm), succinate (2.39 ppm) and  $\beta$ -alanine (3.16, 2.54 ppm). Variations along the y-axis include increases in arginine (1.92, 1.64 ppm) and  $\beta$ -alanine. The scores of the A $\beta$ 42+PI3K-expressing flies were then calculated. As seen in Fig. 4A, the values fall between the control and PI3K scores and show no overlap with those of A $\beta$ 42, indicating that co-expression of PI3K essentially reverts the metabolic effects of A $\beta$ 42.

To further analyze the effect of A $\beta$ 42-expression, and that of its co-expression with PI3K, an OPLS-DA model was made to separate A $\beta$ 42 flies from both control and PI3K-expressing flies (Fig. 4B). A $\beta$ 42-expressing flies had higher levels of histidine and lysine and lower



**Fig. 4. NMR show a robust metabolite response to high A $\beta$ 42 concentrations which is largely reversed by co-expression of PI3K.**

(A) O2PLS-DA model separating metabolite profiles of control, A $\beta$ 42- and PI3K-expressing flies. The cross-validated scores of control (green), A $\beta$ 42- (blue) and PI3K-expressing (red) flies show a robust separation of the three groups. The scores of A $\beta$ 42+PI3K-expressing flies were predicted based on this model. The values show that co-expression of PI3K reverses the metabolic effects of A $\beta$ 42. Metabolite variations along the x-axis include increases in glucose, histidine, uracil, phosphocholine and lysine, and decreases in maltose, uridine, succinate and  $\beta$ -alanine, and variations along the y-axis include increases in arginine and  $\beta$ -alanine. (B) OPLS-DA model separating metabolite profiles of A $\beta$ 42 from control and PI3K-expressing flies. There is a clear separation of the cross-validated scores. The scores of A $\beta$ 42+PI3K flies are similar to control and PI3K. Thus, PI3K prevents the metabolic effects of A $\beta$ 42 at day 7 and 15. Metabolite differences are indicated under the scores plot. Box and whisker plots indicate the median, the first and third quartiles, and the minimum and maximum score values. (C) Relative metabolite concentrations. Colors are as in A. Concentrations were normalized to the median in control flies.

In contrast, A $\beta$ 42+PI3K-expressing flies were not different from control and PI3K-expressing flies (Table S1). Finally, we examined the variation in concentration of the affected metabolites as a function of time and expressed proteins. Relative concentrations of maltose, histidine, lysine, uridine,  $\beta$ -alanine and succinate are shown in Fig. 4C. Notably, all A $\beta$ 42-induced metabolite changes except the increase in histidine were reversed by PI3K.

It is widely accepted that neurons produce the majority of A $\beta$  in an activity-dependent manner (Kamenetz et al., 2003). However, several studies have demonstrated that glial cells also play important roles in AD pathology (De Strooper and Karran, 2016). Actually, AD patients often die by bronchopneumonia and cardiovascular diseases (Brunnström and Englund, 2009; Attems et al., 2005) rather than by neuronal loss. These facts argue that A $\beta$  toxicity in non-neuronal tissues could contribute to the eventual death of the patients, and justified our evaluation of A $\beta$ 42 in neurosecretory and epithelial tissues in search for an early diagnosis.

In leukokinin cells, A $\beta$ 42 generates an inflated abdomen akin to that described in *Drosophila* renal failure models (Denholm, 2013). Leucokinin, analog of mammalian vasopressin, regulates Malpighian tubule fluid secretion, diuresis, fluid balance (Terhzaz et al., 1999; Chen et al., 1994) and cardio and respiratory regulation in insects (Cantera and Nässel, 1992). A $\beta$ 42 toxicity in neurosecretory cells cannot be related to synapses because these cells lack synapsin, subsynaptic reticulum and synaptic specializations altogether (Landgraf et al., 2003). Peptide secretion uses mechanisms different from those for neurotransmitter release in synapses (Mansvelter and Kits, 2000). The toxicity of A $\beta$ 42 in epithelial cells points towards a more basic reason which, eventually, leads to activation of Caspase-3. One of these basic mechanisms seems to be defective Wg signaling.

The metabolite variations include increases in glucose, histidine, uracil, phosphocholine and lysine in A $\beta$ 42 and increases in maltose, uridine, succinate and  $\beta$ -alanine in PI3K flies (Peterson et al., 1998). Interestingly, uracil is metabolically connected to uridine and  $\beta$ -alanine by one and three enzymatic steps, respectively. Both equilibria are shifted towards uracil in A $\beta$ 42 flies. A $\beta$ 42-expressing flies had higher levels of histidine and lysine and lower levels of maltose, uridine,  $\beta$ -alanine and succinate (Fig. 4B) than control and PI3K flies. Histidine is a precursor for histamine and carnosine biosynthesis, and a powerful antioxidant and anti-inflammatory factor (Peterson et al., 1998). Increased histidine levels were observed in response to acute stress and artificial selection for stress resistance in *Drosophila* (Malmendal et al., 2013; Overgaard et al., 2007). Histidine has earlier been shown to increase in *Drosophila*

levels of maltose, uridine,  $\beta$ -alanine and succinate (Fig. 4B). The predicted scores of the A $\beta$ 42+PI3K-expressing flies also show a reversion of the effect of A $\beta$ 42-expression.

To compare the effects of A $\beta$ 42 and PI3K expression, OPLS-DA models were also made for PI3K expression versus control and A $\beta$ 42 expression, and for A $\beta$ 42+PI3K expression versus control and PI3K expression (Table S1). PI3K-expressing flies were also different from control and A $\beta$ 42-expressing flies and showed higher levels of maltose and lower levels of histidine, lysine and potentially arginine.

expressing both benign and toxic A $\beta$  (Ott et al., 2016), which is very similar to the present system where histidine increased in A $\beta$ 42 flies, independent of co-expression of PI3K. In humans, high histidine was found in urine from patients with Parkinson's disease (Luan et al., 2015), and additional high levels of lysine were found in plasma from patients with mild cognitive impairment (Trushina et al., 2013).

Maltose has been suggested to have a chaperone-like function (Kaplan and Guy, 2004; Pereira and Hünenberger, 2006) and increased levels were observed in *Drosophila* expressing non-toxic levels of A $\beta$ 40 and A $\beta$ 42 and in short and long-term stress responses (Ott et al., 2016; Malmendal et al., 2013; Overgaard et al., 2007). Uridine is precursor of phosphatidylcholine, a major component of cellular membranes, and a reduction in cerebrum-spinal fluid (CSF) of AD patients was suggested to be linked to neuronal deficits (Czech et al., 2012).  $\beta$ -alanine is related to inhibitory neurotransmitters (Mori et al., 2001). Succinate serves as an electron donor to the transport chain in the citric acid cycle and lower levels were found in CSF of AD patients (Redjems-Bennani et al., 1998) and in all brain regions in an AD mouse model (Salek et al., 2010).

The A $\beta$ 42-induced metabolite changes agree with those caused by toxic Arctic A $\beta$ 42 (E22G) relative to non-toxic levels of A $\beta$ 42 and A $\beta$ 40 in abdomens (Ott et al., 2016) in that we see an increase in histidine and a decrease in maltose in both systems (Fig. 4B,C). However, we do not detect increases in gluconic acid and a potentially hydroxylated aromatic compound. This suggests a somewhat different response in the highly expressing A $\beta$ 42 flies or, more general, specificity in the metabolic signature caused by different A $\beta$  peptides (Grochowska et al., 2017).

## MATERIALS AND METHODS

### Fly strains

The following strains were obtained from the Bloomington Stock Center (NIH P40OD018537) (<http://flystocks.bio.indiana.edu/>): *elav<sup>155</sup>-Gal4*, BL-458 (Lin and Goodman, 1994); *D42-Gal4*, BL-8816 (Chan et al., 2002); *engrailed-Gal4*, BL-1973 (Lawrence et al., 1995); *Tubulin-Gal80<sup>TS</sup>*, BL-7019 (McGuire et al., 2003); *UAS-LacZ*, BL-1776 (Brand and Perrimon, 1993); *UAS-PI3K<sup>CAAX</sup>* BL-8294 (Parrish et al., 2009) and *UAS-G-TRACE* BL-28280 (Evans et al., 2009). In addition, we obtained the lines: *leucokinin<sup>M7</sup>-Gal4* from Dr F. Benjumea (Center for Molecular Biology, Madrid, Spain) (de Haro et al., 2010) and *UAS-A $\beta$ 42(2x)* from Dr P. Fernández-Fúnez (University of Florida, USA) (Casas-Tintó et al., 2011). The *UAS-A $\beta$ 42(2x)* construct contains two copies of the gene encoding the human A $\beta$ 42 peptide which has proven effective to cause  $\beta$ -amyloid deposits immune-positive for 6E10 antibody (Covance catalog # SIG-39320).

### Activation of the Gal4/UAS system and sample preparation

Flies of genotypes containing the Gal4/UAS/Gal80<sup>TS</sup> constructs were grown at 17°C, and transferred to 29°C as 0–3-day-old adults to allow the expression of the Gal4. The three days of adulthood prior to the onset of Gal4 expression were required to allow maturation of adult neural structures. Flies of the desired age with the Gal4 system activated (see diagram in Fig. 1) were collected, rapidly frozen in liquid nitrogen and stored at –80°C until the required amount was obtained. Using a sieve of appropriate size, thorax-abdomen samples were obtained and used for further processing under NMR (see below).

### Immunostaining

Third instar larval tissues and adult brains were dissected and fixed with 4% formaldehyde in phosphate-buffered saline for 20 min, washed three times with PBS1×0.1% Triton-X, and mounted in Vectashield medium with DAPI, or incubated with primary and secondary antibodies. The following antibodies and dilutions were used: anti-Wingless mouse 1:20 (DSHB); anti-Activated caspase-3 IHC rabbit 1:100 (Cell Signal) and anti-Armadillo mouse 1:50 (DSHB). Preparations were imaged in a Leica SP5 confocal microscope and images were processed by ImageJ (NIH).

### Sample preparation for NMR

For each condition we prepared three replicates of 20 pooled fly thorax-abdomens for NMR spectroscopy. Samples were directly lyophilized and stored at 4°C (Jensen et al., 2013). Materials were mechanically homogenized with a TissueLyzer (Quiagen) in 1 ml of ice-cold acetonitrile (50%) for 3×1 min. Hereafter samples were centrifuged (10,000 g) for 10 min at 4°C and the supernatant (900  $\mu$ l) was transferred to new tubes, snap frozen and stored at –80°C. The supernatant was then lyophilized and stored at –80°C. Immediately before NMR measurements, samples were rehydrated in 200 ml of 50 mM phosphate buffer (pH 7.4) in D<sub>2</sub>O, and 180 ml was transferred to 3 mm NMR tubes. The buffer contained 50 mg/l of the chemical shift reference 3-(trimethylsilyl)-propionic acid-D<sub>4</sub>, sodium salt (TSP), and 50 mg/l of sodium azide to prevent bacterial growth.

### NMR experiments

NMR measurements were performed at 25°C on a Bruker Avance III HD 800 spectrometer (Bruker Biospin, Rheinstetten, Germany), operating at a <sup>1</sup>H frequency of 799.87 MHz, equipped with a 3 mm TCI cold probe. <sup>1</sup>H NMR spectra were acquired using a single 90°-pulse experiment with a Carr-Purcell-Meiboom-Gill (CPMG) delay added, in order to attenuate broad signals from high-molecular-weight components. The total CPMG delay was 194 ms and the spin-echo delay was 4 ms. The water signal was suppressed by excitation sculpting, potentially masking changes in metabolites (mostly sugar units) resonating in this region. A total of 128 transients of 32 K data points spanning a spectral width of 20 ppm were collected, corresponding to a total experimental time of 6.5 min.

### NMR data and analyses

The spectra were processed using iNMR ([www.inmr.net](http://www.inmr.net)). An exponential line-broadening of 0.5 Hz was applied to the free-induction decay prior to Fourier transformation. All spectra were referenced to the TSP signal at –0.017 ppm, automatically phased and baseline corrected. The spectra were aligned using *icoshift* (Savorani et al., 2010). The spectra were normalized to total intensity in order to suppress separation based on variations in amount of sample. Metabolite assignments were done based on chemical shifts only, using earlier assignments and spectral databases previously described (Bertram et al., 2006; Cui et al., 2008; Malmendal et al., 2006; Ott et al., 2016), and comparison with *Drosophila* metabolites identified by mass spectrometry (Chintapalli et al., 2013). NMR spectra with the resulting assigned metabolites are provided in Fig. S1.

Although unsupervised methods like principal component analysis (PCA) are highly informative when analyzing differences in metabolite profiles, other effects may hide the variation of interest. Thus, orthogonal projection to latent structures discriminant analysis (O2PLS-DA) (Trygg and Wold, 2003) was used to focus the analysis on the variation that separates the different combinations of protein expression and age. The O2PLS-DA models were carried out on Pareto-scaled data. They were validated by cross validation, where randomly chosen groups of samples were left out to predict group membership for the excluded samples, until predicted values had been obtained for all samples.

O2PLS-DA was used to make a model separating 7–10 and 15–18-day-old control, A $\beta$ 42 and PI3K in to three groups. Similarly, OPLS-DA was used to make a model separating A $\beta$ 42 from control and PI3K in 7–10 and 15–18-day-old flies together. In both cases the relative similarity of the A $\beta$ 42+PI3K flies to the separated groups was estimated. Models for PI3K versus control and A $\beta$ 42 and A $\beta$ 42+PI3K versus control and PI3K were also made for 7–10 and 15–18-day-old flies together.

We also tested which metabolites correlated with the overall between group differences in the metabolome. Significant spectral correlations were identified by applying sequential Bonferroni correction ( $P < 0.05$ ) for an assumed total number of 100 metabolites.

### Acknowledgements

The authors thank Göran Karlsson and Anders Pedersen at the Swedish NMR Center at the University of Gothenburg for help with sample preparation and experimental setup and for the use of their 800 MHz spectrometer. We also thank the Fly Stock Center at Bloomington (Indiana, USA) (<http://flystocks.bio.indiana.edu/>), and lab colleagues for critical reading of the manuscript.

## Competing interests

The authors declare no competing or financial interests.

## Author contributions

Investigation: M.A., S.C.-T., A.M., A.F.; Writing - original draft preparation: M.A., S.C.-T., A.M., A.F.; Writing - review and editing: M.A., S.C.-T., A.M., A.F.

## Funding

S.C.-T. holds a contract from the Ramón y Cajal program RYC-2012-11410. Research has been funded by grant BFU2012-38191 (A.F.) and BFU2015-65685P (S.C.-T. and A.F.) from the Spanish Ministry of Economy, and the COST Action PROTEOSTASIS BM1307 (A.F.).

## Supplementary information

Supplementary information available online at <http://bio.biologists.org/lookup/doi/10.1242/bio.029991.supplemental>

## References

- Al-Anzi, B., Armand, E., Nagamei, P., Olszewski, M., Sapin, V., Waters, C., Zinn, K., Wyman, R. J. and Benzer, S. (2010). The leucokinin pathway and its neurons regulate meal size in *Drosophila*. *Curr. Biol.* **20**, 969-978.
- Andrew, R. J., Kellett, K. A. B., Thinakaran, G. and Hooper, N. M. (2016). A Greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteolysis. *J. Biol. Chem.* **291**, 19235-19244.
- Askanas, V. and Engel, W. K. (1998). Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain: recent approaches to diagnosis and pathogenesis, and relation to aging. *Scand. J. Rheumatol.* **27**, 389-405.
- Attems, J., König, C., Huber, M., Lintner, F. and Jellinger, K. A. (2005). Cause of death in demented and non-demented elderly inpatients; an autopsy study of 308 cases. *J. Alzheimers Dis.* **8**, 57-62.
- Barba, I., Fernandez-Montesinos, R., Garcia-Dorado, D. and Pozo, D. (2008). Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. *J. Cell. Mol. Med.* **12**, 1477-1485.
- Bertram, H. C., Bach Knudsen, K. E., Serena, A., Malmendal, A., Nielsen, N. C., Fretté, X. C. and Andersen, H. J. (2006). NMR-based metabolomic studies reveal changes in the biochemical profile of plasma and urine from pigs fed high-fibre rye bread. *Br. J. Nutr.* **95**, 955-962.
- Bolduc, D. M., Montagna, D. R., Seghers, M. C., Wolfe, M. S. and Selkoe, D. J. (2016). The amyloid-beta forming tripeptide cleavage mechanism of gamma-secretase. *Elife* **5**, e17578.
- Brand, A. H. and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401-415.
- Brunnström, H. R. and Englund, E. M. (2009). Cause of death in patients with dementia disorders. *Eur. J. Neurol.* **16**, 488-492.
- Busciglio, J., Gabuzda, D. H., Matsudaira, P. and Yankner, B. A. (1993). Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. *Proc. Natl. Acad. Sci. USA* **90**, 2092-2096.
- Cantera, R. and Nässel, D. R. (1992). Segmental peptidergic innervation of abdominal targets in larval and adult dipteran insects revealed with an antiserum against leucokinin I. *Cell Tissue Res.* **269**, 459-471.
- Card, J. P., Meade, R. P. and Davis, L. G. (1988). Immunocytochemical localization of the precursor protein for beta-amyloid in the rat central nervous system. *Neuron* **1**, 835-846.
- Casas-Tintó, S., Zhang, Y., Sanchez-Garcia, J., Gomez-Velazquez, M., Rincon-Limas, D. E. and Fernandez-Funez, P. (2011). The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. *Hum. Mol. Genet.* **20**, 2144-2160.
- Casas-Tintó, S., Arnés, M. and Ferrús, A. (2017). *Drosophila* enhancer-Gal4 lines show ectopic expression during development. *R. Soc. Open Sci.* **4**, 170039.
- Chan, H. Y. E., Warrick, J. M., Andriola, I., Merry, D. and Bonini, N. M. (2002). Genetic modulation of polyglutamine toxicity by protein conjugation pathways in *Drosophila*. *Hum. Mol. Genet.* **11**, 2895-2904.
- Chen, Y., Veenstra, J. A., Hagedorn, H. and Davis, N. T. (1994). Leucokinin and diuretic hormone immunoreactivity of neurons in the tobacco hornworm, *Manduca sexta*, and co-localization of this immunoreactivity in lateral neurosecretory cells of abdominal ganglia. *Cell Tissue Res.* **278**, 493-507.
- Chintapalli, V. R., Al Bratty, M., Korzekwa, D., Watson, D. G. and Dow, J. A. T. (2013). Mapping an atlas of tissue-specific *Drosophila melanogaster* metabolomes by high resolution mass spectrometry. *PLoS ONE* **8**, e78066.
- Cuesto, G., Enriquez-Barreto, L., Carames, C., Cantarero, M., Gasull, X., Sandi, C., Ferrus, A., Acebes, A. and Morales, M. (2011). Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. *J. Neurosci.* **31**, 2721-2733.
- Cuesto, G., Jordán-Álvarez, S., Enriquez-Barreto, L., Ferrús, A., Morales, M. and Acebes, A. (2015). GSK3beta inhibition promotes synaptogenesis in *Drosophila* and mammalian neurons. *PLoS ONE* **10**, e0118475.
- Cui, Q., Lewis, I. A., Hegeman, A. D., Anderson, M. E., Li, J., Schulte, C. F., Westler, W. M., Eghbalnia, H. R., Sussman, M. R. and Markley, J. L. (2008). Metabolite identification via the Madison Metabolomics Consortium Database. *Nat. Biotechnol.* **26**, 162-164.
- Czech, C., Berndt, P., Busch, K., Schmitz, O., Wiemer, J., Most, V., Hampel, H., Kastler, J. and Senn, H. (2012). Metabolite profiling of Alzheimer's disease cerebrospinal fluid. *PLoS ONE* **7**, e31501.
- de Haro, M., Al-Ramahi, I., Benito-Sipos, J., López-Arias, B., Dorado, B., Veenstra, J. A. and Herrero, P. (2010). Detailed analysis of leucokinin-expressing neurons and their candidate functions in the *Drosophila* nervous system. *Cell Tissue Res.* **339**, 321-336.
- De Strooper, B. and Karran, E. (2016). The cellular phase of Alzheimer's disease. *Cell* **164**, 603-615.
- Denholm, B. (2013). Shaping up for action: the path to physiological maturation in the renal tubules of *Drosophila*. *Organogenesis* **9**, 40-54.
- Evans, C. J., Olson, J. M., Ngo, K. T., Kim, E., Lee, N. E., Kuoy, E., Patananan, A. N., Sitz, D., Tran, P. T., Do, M.-T. et al. (2009). G-TRACE: rapid Gal4-based cell lineage analysis in *Drosophila*. *Nat. Methods* **6**, 603-605.
- Franciscovich, A. L., Mortimer, A. D. V., Freeman, A. A., Gu, J. and Sanyal, S. (2008). Overexpression screen in *Drosophila* identifies neuronal roles of GSK-3 beta/shaggy as a regulator of AP-1-dependent developmental plasticity. *Genetics* **180**, 2057-2071.
- Gerber, H., Wu, F., Dimitrov, M., Garcia Osuna, G. M. and Fraering, P. C. (2017). Zinc and copper differentially modulate amyloid precursor protein processing by gamma-secretase and amyloid-beta peptide production. *J. Biol. Chem.* **292**, 3751-3767.
- Grochowska, K. M., Yuanxiang, P. A., Bär, J., Raman, R., Brugal, G., Sahu, G., Schweizer, M., Bikbaev, A., Schilling, S., Demuth, H. U. et al. (2017). Posttranslational modification impact on the mechanism by which amyloid-beta induces synaptic dysfunction. *EMBO Rep.* **18**, 962-981.
- Hay, B. A., Wolff, T. and Rubin, G. M. (1994). Expression of baculovirus P35 prevents cell death in *Drosophila*. *Development* **120**, 2121-2129.
- Inestrosa, N. C. and Varela-Nallar, L. (2014). Wnt signaling in the nervous system and in Alzheimer's disease. *J. Mol. Cell Biol.* **6**, 64-74.
- Jensen, K., Sanchez-Garcia, J., Williams, C., Khare, S., Mathur, K., Graze, R. M., Hahn, D. A., McIntyre, L. M., Rincon-Limas, D. E., Fernandez-Funez, P. (2013). Purification of transcripts and metabolites from *Drosophila* heads. *J. Vis. Exp.*, e50245.
- Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S. and Malinow, R. (2003). APP processing and synaptic function. *Neuron* **37**, 925-937.
- Kaplan, F. and Guy, C. L. (2004). beta-Amylase induction and the protective role of maltose during temperature shock. *Plant Physiol.* **135**, 1674-1684.
- Landgraf, M., Sánchez-Soriano, N., Technau, G. M., Urban, J. and Prokop, A. (2003). Charting the *Drosophila* neuropile: a strategy for the standardised characterisation of genetically amenable neurites. *Dev. Biol.* **260**, 207-225.
- Lawrence, P. A., Bodmer, R. and Vincent, J. P. (1995). Segmental patterning of heart precursors in *Drosophila*. *Development* **121**, 4303-4308.
- Lei, M., Xu, H., Li, Z., Wang, Z., O'Malley, T. T., Zhang, D., Walsh, D. M., Xu, P., Selkoe, D. J. and Li, S. (2016). Soluble Aβ oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance. *Neurobiol. Dis.* **85**, 111-121.
- Lin, D. M. and Goodman, C. S. (1994). Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. *Neuron* **13**, 507-523.
- López-Arias, B., Dorado, B. and Herrero, P. (2011). Blockade of the release of the neuropeptide leucokinin to determine its possible functions in fly behavior: chemoreception assays. *Peptides* **32**, 545-552.
- Luan, H., Liu, L.-F., Tang, Z., Zhang, M., Chua, K.-K., Song, J.-X., Mok, V. C. T., Li, M. and Cai, Z. (2015). Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease. *Sci. Rep.* **5**, 13888.
- Ludewig, S. and Korte, M. (2016). Novel insights into the physiological function of the APP (gene) family and its proteolytic fragments in synaptic plasticity. *Front. Mol. Neurosci.* **9**, 161.
- Malmendal, A., Overgaard, J., Bundy, J. G., Sorensen, J. G., Nielsen, N. C., Loeschcke, V. and Holmstrup, M. (2006). Metabolomic profiling of heat stress: hardening and recovery of homeostasis in *Drosophila*. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **291**, R205-R212.
- Malmendal, A., Sørensen, J. G., Overgaard, J., Holmstrup, M., Nielsen, N. C. and Loeschcke, V. (2013). Metabolomic analysis of the selection response of *Drosophila melanogaster* to environmental stress: are there links to gene expression and phenotypic traits? *Naturwissenschaften* **100**, 417-427.
- Mansvelder, H. D. and Kits, K. S. (2000). Calcium channels and the release of large dense core vesicles from neuroendocrine cells: spatial organization and functional coupling. *Prog. Neurobiol.* **62**, 427-441.
- Mapstone, M., Lin, F., Nalls, M. A., Cheema, A. K., Singleton, A. B., Fiandaca, M. S. and Federoff, H. J. (2017). What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. *Neurobiol. Aging* **51**, 148-155.

- Martin-Pena, A., Acebes, A., Rodriguez, J.-R., Sorribes, A., de Polavieja, G. G., Fernandez-Funez, P. and Ferrus, A. (2006). Age-independent synaptogenesis by phosphoinositide 3 kinase. *J. Neurosci.* **26**, 10199-10208.
- McGuire, S. E., Le, P. T., Osborn, A. J., Matsumoto, K. and Davis, R. L. (2003). Spatiotemporal rescue of memory dysfunction in *Drosophila*. *Science* **302**, 1765-1768.
- Mori, M., Heuss, C., Gähwiler, B. H. and Gerber, U. (2001). Fast synaptic transmission mediated by P2X receptors in CA3 pyramidal cells of rat hippocampal slice cultures. *J. Physiol.* **535**, 115-123.
- Noordermeer, J., Klingensmith, J., Perrimon, N. and Nusse, R. (1994). Dishevelled and armadillo act in the wingless signalling pathway in *Drosophila*. *Nature* **367**, 80-83.
- Ott, S., Vishnivetskaya, A., Malmendal, A. and Crowther, D. C. (2016). Metabolic changes may precede proteostatic dysfunction in a *Drosophila* model of amyloid beta peptide toxicity. *Neurobiol. Aging* **41**, 39-52.
- Overgaard, J., Malmendal, A., Sørensen, J. G., Bundy, J. G., Loeschcke, V., Nielsen, N. C. and Holmstrup, M. (2007). Metabolomic profiling of rapid cold hardening and cold shock in *Drosophila melanogaster*. *J. Insect Physiol.* **53**, 1218-1232.
- Parrish, J. Z., Xu, P., Kim, C. C., Jan, L. Y. and Jan, Y. N. (2009). The microRNA bantam functions in epithelial cells to regulate scaling growth of dendrite arbors in *Drosophila* sensory neurons. *Neuron* **63**, 788-802.
- Pereira, C. S. and Hünenberger, P. H. (2006). Interaction of the sugars trehalose, maltose and glucose with a phospholipid bilayer: a comparative molecular dynamics study. *J. Phys. Chem. B* **110**, 15572-15581.
- Perez-Garijo, A., Martin, F. A., Struhl, G. and Morata, G. (2005). Dpp signaling and the induction of neoplastic tumors by caspase-inhibited apoptotic cells in *Drosophila*. *Proc. Natl. Acad. Sci. USA* **102**, 17664-17669.
- Perez-Garijo, A., Shlevkov, E. and Morata, G. (2009). The role of Dpp and Wg in compensatory proliferation and in the formation of hyperplastic overgrowths caused by apoptotic cells in the *Drosophila* wing disc. *Development* **136**, 1169-1177.
- Peterson, J. W., Boldogh, I., Popov, V. L., Saini, S. S. and Chopra, A. K. (1998). Anti-inflammatory and antisecretory potential of histidine in *Salmonella*-challenged mouse small intestine. *Lab. Invest.* **78**, 523-534.
- Portela, M., Casas-Tinto, S., Rhiner, C., López-Gay, J. M., Domínguez, O., Soldini, D. and Moreno, E. (2010). *Drosophila* SPARC is a self-protective signal expressed by loser cells during cell competition. *Dev. Cell* **19**, 562-573.
- Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M. and Zhang, J. (2017). Mass-spectrometry-based method to quantify in parallel tau and amyloid beta 1-42 in CSF for the diagnosis of Alzheimer's disease. *J. Proteome Res.* **16**, 1228-1238.
- Redjems-Bennani, N., Jeandel, C., Lefebvre, E., Blain, H., Vidailhet, M. and Gueant, J.-L. (1998). Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. *Gerontology* **44**, 300-304.
- Riggleman, B., Schedl, P. and Wieschaus, E. (1990). Spatial expression of the *Drosophila* segment polarity gene armadillo is posttranscriptionally regulated by wingless. *Cell* **63**, 549-560.
- Salek, R. M., Xia, J., Innes, A., Sweatman, B. C., Adalbert, R., Randle, S., McGowan, E., Emson, P. C. and Griffin, J. L. (2010). A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. *Neurochem. Int.* **56**, 937-947.
- Savorani, F., Tomasi, G. and Engelsen, S. B. (2010). icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. *J. Magn. Reson.* **202**, 190-202.
- Seipold, L. and Saftig, P. (2016). The emerging role of tetraspanins in the proteolytic processing of the amyloid precursor protein. *Front. Mol. Neurosci.* **9**, 149.
- Sofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., Allen, M. J., Hardy, J., Lovestone, S. and Partridge, L. (2010). Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset *Drosophila* model of Alzheimer's disease. *PLoS Genet.* **6**, e1001087.
- Somers, C., Goossens, J., Engelborghs, S. and Bjerke, M. (2017). Selecting Abeta isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. *Biomark Med.* **11**, 169-178.
- Terhzaz, S., O'Connell, F. C., Pollock, V. P., Kean, L., Davies, S. A., Veenstra, J. A. and Dow, J. A. (1999). Isolation and characterization of a leucokinin-like peptide of *Drosophila melanogaster*. *J. Exp. Biol.* **202**, 3667-3676.
- Trushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M. and Petersen, R. C. (2013). Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. *PLoS ONE* **8**, e63644.
- Trygg, J. and Wold, S. (2003). O2-PLS, a two-block (X-Y) latent variable regression (LVR) method with an integral OSC filter. *J. Chemometrics* **17**, 53-64.
- Vincent, J.-P., Kolahgar, G., Gagliardi, M. and Piddini, E. (2011). Steep differences in wingless signaling trigger Myc-independent competitive cell interactions. *Dev. Cell* **21**, 366-374.
- Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J. and Selkoe, D. J. (2002). Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. *Biochem. Soc. Trans.* **30**, 552-557.
- Westmark, C. J., Sokol, D. K., Maloney, B. and Lahiri, D. K. (2016). Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. *Mol. Psychiatry* **21**, 1333-1341.